Similarly, in advanced, immunologically “cold” melanoma, MG1 combined with anti-PD-1 therapy partially reversed immune suppression, enhanced CD8+ T cell responses, and extended survival compared with monotherapy (~77.5 vs. ~41–46 days) [136]. The gene discussed is CD8A; the disease is melanoma.